How profitable is BeyondSpring Inc. (BYSI)?

In FY 2025 (10-K), BYSI converted $25.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / BYSI / financials

BCTX (40) ABVC (32) CPHI (35) CELU (26) ⌘ Pro Terminal →

BeyondSpring Inc. (BYSI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.64 +24.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.67

BeyondSpring Inc. (BYSI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $26.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BYSI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BeyondSpring Inc. (NASDAQ: BYSI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.64 (+24.60% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BYSI ranks #546 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BYSI compare to BCTX and ABVC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BYSI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCTX (BriaCell Therapeutics Corp.) holds a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BYSI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BYSI?

▼

Per BYSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001677940), BeyondSpring Inc. generated $25.0M in revenue (+2.2% YoY), -$1.0M in net income, and -$19.8M in free cash flow against $25.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.67 (+4.24%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BYSI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY BYSI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 53.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.61-14.8% Next Q

Q2 (-2Q)

Grade E$0.52-11.5% Next Q

Q3 (-1Q)

Grade E$0.46+39.1% Next Q

Current

Grade D-$0.64-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BYSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BYSI currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.67) forces dealer call-delta covering toward $2.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BYSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BYSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BYSI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $42.2M

FY24

Rev $24.5M

FY25

Rev $25.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$25.0M	52%	-35.7%	-$1.0M	-$19.8M	-45%
FY 2024	$24.5M	52%	-35.7%	-$11.1M	-$16.7M	-45%
FY 2023	$42.2M	52%	-35.7%	-$21.0M	-$16.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BYSI)

✓Walkthrough of BYSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BYSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.62%▼ DESCENDING CHANNEL

2026-11-03O $0.51H $0.64L $0.51C $0.64VOL 219.1K

RES: $0.96SUP: $0.39SMA50: $0.65SMA200: $1.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BYSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BYSI Butterfly Map → + Track BYSI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BYSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BYSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BYSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BYSI)

Health Care Rank #546 of 1016 ⚔️ BCTX vs BYSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BYSI vs. BCTX, ABVC, CPHI, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BeyondSpring Inc. (BYSI) ranks #546 by composite RQD confidence (37/100, grade D-) and #812 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, BYSI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BYSI at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BYSI ACTIVE BeyondSpring Inc.	D-	37/100	—	—	-35.0%	+24.60%	$26.5M	Benchmark Subject
BCTX BriaCell Therapeutics Corp.	D-	40/100	—	—	—	-8.16%	$26.5M	/bctx-vs-bysi →
ABVC ABVC BioPharma Inc.	E	32/100	—	—	-35.0%	-3.85%	$26.7M	/abvc-vs-bysi →
CPHI China Pharma Holdings Inc.	D-	35/100	—	-3.2%	-11.4%	-3.86%	$26.9M	/cphi-vs-bysi →
CELU Celularity Inc. (Class A)	E	26/100	—	24.4%	-35.0%	-5.79%	$26.0M	/celu-vs-bysi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001677940

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BeyondSpring Inc. (BYSI) reported GAAP revenue of $25.0M (+2.2% vs. FY2024 revenue of $24.5M , and -40.7% cumulative change since FY2023) , GAAP net income of -$1.0M, operating cash flow of -$19.8M, and free cash flow of -$19.8M (-18.9% YoY). On the balance sheet, BYSI closed FY2025 with $25.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$25.0M	-$1.0M	-$19.8M	-$19.8M	$25.9M	—
FY2024 (FY)	2024-12-31	$24.5M	-$11.1M	-$16.4M	-$16.7M	$34.3M	—
FY2023 (FY)	2023-12-31	$42.2M	-$21.0M	-$16.5M	-$16.5M	—	—

3. BYSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BYSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BYSI compare to BCTX and ABVC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BYSI?

Where is BYSI trading relative to its 50-day, 200-day, and 52-week technical levels?

BYSI last traded at $0.64 (+24.60% on volume of 219,060 shares), positioning the stock -1.54% below its 50-day simple moving average ($0.65) and -49.21% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.42 to $2.44, BYSI sits at the 10.9% percentile with a 14-day RSI of 53.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.72).

Direct Sub-Reports: BYSI RQD Cockpit BYSI 12M Forecast BYSI Earnings & Move BYSI Dividends & DRIP BYSI Insiders & 13F BYSI Whale Options BYSI Profit Sankey BYSI News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BYSI — BeyondSpring Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:43Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

BYSI scores 34 out of 100, earning an E grade and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. FY 2025 free cash flow was -$19.8M against operating income of -$8.9M.
Whale / 13F Flow: 6 / 20. The RQD rating describes this pillar as covering institutional accumulation and options positioning. The holders section contains no data, so the score cannot be traced to specific filings in the source data. A low score here suggests limited institutional support in the sourced record.
Insider Conviction: 5 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow.
Macro Regime Fit: 9 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is factored in. A beta of 1.0 indicates market-equivalent sensitivity; the score reflects that the stock does not offer a clear macro-regime tailwind per the rating methodology.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski score of 2 out of 9 is a weak reading on fundamental quality, and the Altman Z of 2.5 sits in the zone the rating treats as a meaningful but not extreme distress signal.

Upside drivers, as framed by the data, would require a turn from negative ROIC and negative operating income toward positive cash generation. Valuation tradeoffs are severe: the market capitalization is $21.2M against cash of $7.8M and FCF of -$19.8M, so the equity is priced on expectations the sourced financials do not yet demonstrate. The stock's price of 0.52 sits within a 52-week range of $0.42 - $2.44, meaning it trades near the lower end of its recent band.

2. Business Model, Unit Margins & SEC Financial Trajectory

BeyondSpring Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the sourced periods. Product offerings, customers, and revenue model details are —

Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the RQD rating, Debt/Equity is 0.5, while the SEC financials list debt as N/A for all periods, so the balance sheet posture cannot be fully reconciled from the source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turns positive. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 8/20, sustained execution supports upside toward the top of the $0.42 – $2.44 52-week range.
🐻 Primary Bear Case: ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the Health Care classification: — Second-order bottlenecks: —

Key Question #1: What is the debt position, since the financials list debt as N/A while the RQD rating cites Debt/Equity of 0.5?
Key Question #2: How does the company fund its negative free cash flow, and what is the runway implied by the reported cash of $7.8M?
Key Question #3: Why does the net loss narrow from -$11.1M in FY 2024 to -$1.0M in FY 2025 while operating income remains near -$8.9M?

BYSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BeyondSpring Inc. (BYSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BYSI Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 19h ago

BeyondSpring(BYSI) Stock Options Chain | Quotes & News

Moomoo report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 22h ago

Beyondspring Stock Price Forecast. Should You Buy BYSI?

StockInvest.us report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two funds underpin one manager’s reported passive stake in BeyondSpring (BYSI).

Stock Titan report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

BeyondSpring (BYSI) Slips 3.90% to $0.56 as Shares Press Toward Lower Support - Diagonal Spread Trade

https://www.dars.gov.et/ report covering BeyondSpring Inc. (BYSI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 13h ago

After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket Review

Nov. 2, 2026 postmarket review of after-hours gainers and losers, including PARA, GMEX, BLZE, SXT, HODO and ADEA, with several stocks reversing today's moves.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 18h ago

Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026

Nov. 2, 2026 US market movers: small-cap and micro-cap top gainers and decliners, led by CLRO, INLF, EVGO, DRUG, JDZG and SVRN, with percentage changes and comments.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 3d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BYSI Bull vs. Bear Conversation Board — What's Your Call at $0.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BYSI 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.78 (+21.9%)

📌 Pinned Debate

Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turn

Picked up a starter position in BYSI in my $100K Virtual Cash book at $0.64. Price of 0.52 sits near the bottom of a $0.42 - $2.44 52-week range with a 1.0 beta, leaving room for re-rating if cash generation turns positive.. Trading inside a $0.42–$2.44 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.52 (-18.8%)

Spot @ $0.64

ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.

Fading this rally in BYSI at $0.64. ROIC of -35%, FCF of -$19.8M against $7.8M cash, and a Piotroski F-Score of 2/9 point to a cash engine that is not yet self-funding.. With a beta of 1.0 and the stock sitting at $0.64 (52-wk range $0.42–$2.44), the easy multiple expansion is already priced in.